Decoding Drug Discovery: Exploring A-to-Z In silico Methods for Beginners

TL;DR

This paper reviews a comprehensive range of in silico methods used in drug discovery, emphasizing their role in efficiently identifying therapeutic targets and accelerating the development process.

Contribution

It provides an extensive overview of A-to-Z computational techniques in drug target identification, highlighting their potential to improve efficiency and success rates in drug development.

Findings

In silico methods can significantly reduce drug discovery time.

These techniques enhance the identification of disease-specific therapeutic targets.

In silico approaches improve the efficiency of clinical trial planning.

Abstract

The drug development process is a critical challenge in the pharmaceutical industry due to its time-consuming nature and the need to discover new drug potentials to address various ailments. The initial step in drug development, drug target identification, often consumes considerable time. While valid, traditional methods such as in vivo and in vitro approaches are limited in their ability to analyze vast amounts of data efficiently, leading to wasteful outcomes. To expedite and streamline drug development, an increasing reliance on computer-aided drug design (CADD) approaches has merged. These sophisticated in silico methods offer a promising avenue for efficiently identifying viable drug candidates, thus providing pharmaceutical firms with significant opportunities to uncover new prospective drug targets. The main goal of this work is to review in silico methods used in the drug development process with a focus on identifying therapeutic targets linked to specific diseases at the genetic or protein level. This article thoroughly discusses A-to-Z in silico techniques, which are essential for identifying the targets of bioactive compounds and their potential therapeutic effects. This review intends to improve drug discovery processes by illuminating the state of these cutting-edge approaches, thereby maximizing the effectiveness and duration of clinical trials for novel drug target investigation.